CA 15-3, ceruloplasmin and tissue polypeptide specific antigen as a tumour marker panel in breast cancer

East African Medical Journal

Volumn 77, Issue 6, 2000, Pages 291-294

  Ozyilkan O ^a,c   Baltali, E ^b   Kirazli, S ^b  

^a BAYINDIR HOSPITAL   (Turkey)

^b HACETTEPE UNIVERSITY   (Turkey)

^c Yukari Dikmen Mah   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

CA 15-3 ANTIGEN; CERULOPLASMIN; TISSUE POLYPEPTIDE ANTIGEN; TUMOR MARKER;

ADOLESCENT; ADULT; AGED; ARTICLE; BREAST TUMOR; FEMALE; HUMAN; MIDDLE AGED; PREDICTION AND FORECASTING; SENSITIVITY AND SPECIFICITY;

ADOLESCENT; ADULT; AGED; BREAST NEOPLASMS; CA-15-3 ANTIGEN; CERULOPLASMIN; FEMALE; HUMANS; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; SENSITIVITY AND SPECIFICITY; TISSUE POLYPEPTIDE ANTIGEN; TUMOR MARKERS, BIOLOGICAL;

EID: 0034344238     PISSN: 0012835X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Bates, S.E. and Longo, D.L. Tumour marker: value and limitation in the management of cancer patients. Cancer Treat. Rev. 1985; 12: 163-207.
2. Hollinshead, A.C. Biological markers of breast cancer: A review. Cancer Invest., 1987; 5:581-591.
3. Duffy, M.J. New cancer markers. Ann. Clin. Biochem., 1989; 26:379-387.
4. Fateh-Maghadam, A., Steiber, P., and Seidel, D. Description of individual tumour markers. In: Sensible use of tumour markers; eds Fateh-Maghadam A, Steiber P, Seidel D, Editiones Roche, Basel, pp 33-49.,1993.
5. Gion, M., Barioli, P., and Mione, R. Tumor markers in breast cancer follow-up: A potentially useful parameter still definitive assessment. Ann. Oncol. 1995; 6: S31-S35
6. Kanapuli, S.P., Singh, H., Singh, P., and Kumar, A. Ceruloplasmin gene expression in human cancer cells. Life Science, 1987; 40:2225-2228.
7. Hrgovcic, M., Tessmer, F., Thomas, F.B., Gambie, J.F., and Shullenberger, C.C. Serum copper observation in patients with malignant Lymphoma. Cancer, 1973; 6:1512-24.
8. Margerison, A.C.F., and Mann, J.R. Serum copper, serum ceruloplasmin, and erythrocyte sedimentation rate measurements in children with Hodgkin's disease, non-Hodgkin's lymphoma and non-malignant lymphadenopathy. Cancer 1985; 55: 1501-6.
9. Sinha, S.N., and Gabrieli, E.R., Serum copper and zinc levels in various pathologic conditions. Amer. J. Clin. Path., 1970; 54: 570-7
10. Zusman, I. Variability of serum tumor-associate antigens and their significance in cancer diagnosis (review). Oncol. Rep. 1994; 1: 997-1009.
11. Eskelinen, M., Hippelainen, M., and Salmela, E. A prospective study of tissue polypeptide specific antigen (TPS) in breast cancer diagnosis. Anticancer Res. 1992; 12:2033-2036.
12. Gion, M., Mione, and R., Gatti, K. Is tissue polypeptide antigen still a useful tumor marker in breast carcinoma? Comparison with CA 15-3 and MCA. Tumori 1990; 76: 360-364.
13. Pujol, J.L., Cooper, E.H., and Grenier, J. Clinical evaluation of serum tissue polypeptide-specific-antigen (TPS) in non-small cell lung cancer. Eur. J. Cancer, 1994; 30A: 1768-1774.
14. Jotti, G.S., and Bombardieri, E. Circulating tumor markers in breast cancer (review). Anticancer Res. 1990; 10: 253-258.
15. Hilkens, J., Buijs, F., Hageman, P.H., Calafat, J., Sonnenberg, A., and van Der Valk, M. Monoclonal antibodies against human milk-fat globule membranes detecting differentiation antigens of the mammary gland and its tumors. Int. J. Cancer, 1984; 34:197-206.
16. Waalkes, T.P., Enterline, J.P., Shaper, J.H., Abeloff, M.D., and Ettinger, D.S. Biological marker for breast carcinoma. Cancer, 1984; 53: 664-671.
17. Stenman, U.K., and Heikkinen, R. Serum markers for breast cancer. Scand. J. Clin. Lab. Invest. 1991; 206p: 52-59
18. Rousse, J., Tubiana-Hulin, M., and Fileul-Saint-Cloud, A. Breast cancer. In: Handbook of chemotherapy in clinical oncology; (Eds), Droz JP, Cvitcovic E, Armand JP and Khoury S. FIIS, Houston, pp 238-245, 1988.
19. Hayes, D.F., Zurawski, V.R., and Kufe, D.W. Comparison of circulation CA 15-3 and carcinoembryonic antigen levels in patients with breast cancer. J. Clin. Oncol. 1986; 4:1542-1550.
20. Schapira, D., and Schapira, M. Use of ceruloplasmin levels to monitor response to therapy and predict recurrence of breast cancer. Breast Cancer Res. Treat., 1983; 3:221-224.
21. Ozyilkan, O., Baltall, E., Ozyilkan, E., Tekuzman, G., Kars, A., and Firat, D. Ceruloplasmin level in women with breast disease: Preliminary results. Acta, Oncologica, 1992; 31:843-846.
22. Bjorklund, B., and Bjorklund, V. Antigenicity of pooled human malignant and normal tissues by cyto-immunological technique: Presence of insoluble, heat-labile tumour antigen. Int. Arch. Allergy 1957; 10: 153-184.
23. Mattson, W., and Borgstrom, S. Tissue Polypeptide Antigen as a Guide in Antineoplastic Treatment of Advanced Mammary Carcinoma. In: Proceeding of the Third International Symposium on Detection and Prevention of Cancer, New York, 1976; 579.
24. Smith, R.E. Biochemical detection of recurrent breast cancer. Cancer Detect Prevent, 1988; 11:303-309.
25. C Hayes D F., Gelman, R., Henderson I.C., and Kufe D.W. Comparison of CA 15-3 and carcinoembryonic antigen in monitoring the clinical course of patients with metastatic breast cancer. Cancer Res. 1988; 48:4107-4712
26. Barak, M., Steiner, M., Finkel, B., Abrahamson, J., Antal, S., and Gruener, N. CA 15-3, TPA and MCA as markers for breast cancer. Eur. J. Cancer, 1990; 26: 577-80.
27. Scwarz, M.K. Cancer markers. In: Cancer: Principles and practice of Oncology. DeVita VT, Hellman S, Rosenberg SA, eds J B Lippincott, Philadelphia, pp 531-542, 1993.
28. van Dalen, A. TPS in breast cancer - A comparative study with carcinoembryonic antigen and CA 15-3. Tumor Biol., 1992; 13: 10-17.
29. Bremer, K. Micus S Bremer, G. and Eberhard, A. A comparison of the clinical relevance of CEA, CA 15-3 and MCA in breast cancer. Onkologie. 1996; 19:170-174.